Drug profile · INN
mirabegron
BETMIGA
mirabegron (BETMIGA) is a beta-3 adrenergic receptor agonist. Associated with Sunshine Guojian Pharmaceutical (Shanghai) Co.,. Route of administration: oral. Current US regulatory status: approved.
Drug details — mirabegron
- US status
- approved
- Class
- Genito-urinary system and sex hormones (G04)
- Route
- ORAL
- Patents
- 1
- Programs
- 7
- Data quality
- 0.89
Quick answer
mirabegron (BETMIGA) is a beta-3 adrenergic receptor agonist. Associated with Sunshine Guojian Pharmaceutical (Shanghai) Co.,. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Beta-3 adrenergic receptor agonist
Primary target: Beta-3 adrenergic receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is mirabegron?
mirabegron (BETMIGA) is a beta-3 adrenergic receptor agonist. Associated with Sunshine Guojian Pharmaceutical (Shanghai) Co.,. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for mirabegron?
BETMIGA is a marketed brand name for mirabegron. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of mirabegron?
mirabegron has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.